ERBB2 and breast carcinoma: A previous study performed with 1702 women with ER +/HER2- breast cancer, similar to our patient, showed that prognostic EndoPredict (EP) score- a multigene score that combines the expression levels of proliferative and ESR1 signalling/differentiation-associated genes, identifies late relapse events[16].